Home›Clinical trials›Virginia

GLP-1 clinical trials in Virginia: 26 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

26 GLP-1 clinical trials are recruiting at 43 sites in 13 cities across Virginia. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Virginia

  1. Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

    Phase 4. University of Virginia plans to enroll 60 participants.

    A study testing whether a GLP-1 medicine, liraglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 21 to 60, have type 2 diabetes.

    1 site in Virginia

    NCT03883412 on ClinicalTrials.gov. See whether you qualify.

  2. Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

    Phase 4. University of Virginia plans to enroll 80 participants.

    A study of a GLP-1 medicine, liraglutide, in people with metabolic syndrome.

    Who can join. Adults 21 to 60, have metabolic syndrome, BMI 25+.

    1 site in Virginia

    NCT04575844 on ClinicalTrials.gov. See whether you qualify.

  3. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    1 site in Virginia

    • Kidney and Hypertension Specialists, PLLC, Manassas. 703-361-7341

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  1. Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction

    Phase 4. University of Virginia plans to enroll 192 participants.

    A study of a GLP-1 medicine, semaglutide, in people with heart failure with preserved ejection fraction.

    Who can join. Adults 18 to 90, have heart failure with preserved ejection fraction.

    1 site in Virginia

    NCT07178145 on ClinicalTrials.gov. See whether you qualify.

  2. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    4 sites in Virginia

    • Eximia Research - Norfolk, Norfolk
    • Richmond Veterans Affairs Medical Center (Richmond VA Medical Center), Richmond
    • Virginia Commonwealth University (VCU) Medical Center, Richmond. 804-828-4060
    • Gastroenterology Consultants of Southwest Virginia, Roanoke

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  3. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Eli Lilly and Company plans to enroll 1,205 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    4 sites in Virginia

    • Stroobants Cardiovascular Center, Lynchburg
    • Carient Heart & Vascular - Manassas, Manassas. 703-335-8750
    • Clinical Research Partners, LLC, Richmond. 804-477-3045
    • Gershon Pain Specialists, Virginia Beach. 757-496-2050

    NCT07223593 on ClinicalTrials.gov. See whether you qualify.

  4. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    3 sites in Virginia

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  5. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    3 sites in Virginia

    • Health Res of Hampton Roads, Newport News
    • Tidewater Physicians Multispecialty Group, Newport News
    • National Clin Res Inc., Richmond

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  6. A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 285 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    3 sites in Virginia

    • Health Res of Hampton Roads, Newport News
    • National Clin Res Inc., Richmond
    • Selma Medical Associates, Winchester

    NCT07745504 on ClinicalTrials.gov. See whether you qualify.

  7. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    2 sites in Virginia

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

The other 16 studies recruiting in Virginia

  1. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    2 sites in Virginia

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  2. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Eli Lilly and Company plans to enroll 1,000 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    2 sites in Virginia

    • Health Research of Hampton Roads, Inc., Newport News. 757-591-8100
    • Urology of Virginia, Virginia Beach

    NCT07202884 on ClinicalTrials.gov. See whether you qualify.

  3. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Kailera plans to enroll 1,200 participants.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Virginia

    • Kailera Clinical Site, Manassas
    • Kailera Clinical Site, Richmond

    NCT07284979 on ClinicalTrials.gov. See whether you qualify.

  4. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    2 sites in Virginia

    • Research Site, Leesburg
    • Research Site, Norfolk

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

  5. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Virginia

    • VCU Health - Center for Endocrinology Diabetes and Metabolism, Richmond

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  6. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Virginia

    • Gastroenterology Consultants of Southwest Virginia, Roanoke

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  7. A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Phase 3. Vanda Pharmaceuticals plans to enroll 280 participants.

    A study testing whether an investigational medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

    Who can join. Adults 18 to 65, have nausea and vomiting, BMI 25+.

    1 site in Virginia

    NCT07446439 on ClinicalTrials.gov. See whether you qualify.

  8. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Virginia

    • Tidewater Physicians Multispecialty Group, Newport News. 833-602-2368

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

  9. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 450 participants.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    1 site in Virginia

    • Selma Medical Associates, Winchester

    NCT07770841 on ClinicalTrials.gov. See whether you qualify.

  10. Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

    Phase 2. University of Virginia plans to enroll 50 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with nafld reduce liver fat.

    Who can join. Adults 18 to 75, have nafld, BMI 27+.

    1 site in Virginia

    • Virginia Commonwealth University, Richmond

    NCT05424003 on ClinicalTrials.gov. See whether you qualify.

  11. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    1 site in Virginia

    • Sovah Clinical Research-River District, Danville. 434-793-4711

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

  12. Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy

    Phase 2. University of Virginia plans to enroll 120 participants.

    A study of a GLP-1 medicine in young people with obesity.

    Who can join. Ages 12 to 21, have obesity.

    1 site in Virginia

    • University of Virginia Medical Center, Charlottesville. 434-243-6911

    NCT06903923 on ClinicalTrials.gov. See whether you qualify.

  13. Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

    Phase 2. University of Colorado, Denver plans to enroll 200 participants.

    A study of a GLP-1 medicine, semaglutide, in women going through menopause.

    Who can join. Adults 45 to 55, women only, are going through menopause.

    1 site in Virginia

    NCT06975111 on ClinicalTrials.gov. See whether you qualify.

  14. Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Biomea Fusion Inc plans to enroll 60 participants.

    A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    1 site in Virginia

    • Burke Internal Medicine and Research, Burke

    NCT07502508 on ClinicalTrials.gov. See whether you qualify.

  15. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Novo Nordisk A/S plans to enroll 230 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Virginia

    • National Clin Res Inc., Richmond

    NCT07639021 on ClinicalTrials.gov. See whether you qualify.

  16. Strength Training Response of Muscle in GLP-1 Users

    Virginia Polytechnic Institute and State University plans to enroll 30 participants.

    A study listed on ClinicalTrials.gov.

    1 site in Virginia

    • Virginia Tech, Blacksburg

    NCT07104539 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.